CAVALLA, Paola
CAVALLA, Paola
NEUROSCIENZE "RITA LEVI MONTALCINI"
A real-world study of Alemtuzumab in a cohort of Italian patients
2019-01-01 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Cyclins and CDKs in classic and anaplastic oligodendroglioma
2003-01-01 Cavalla, P; Fiano, V; Schiffer, D.
Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas
2002-01-01 Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D.
Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia
2002-01-01 Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P.
Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience
2019-01-01 Chisari, C; Comi, G; Zaffaroni, M; Morra, VB; Trojano, M; Iaffaldano, P; Cocco, E; Centonze, D; Uccelli, A; Pozzilli, C; Salemi, G; De Luca, G; Cottone, S; Millefiorini, E; Salvetti, M; Aguglia, U; Costantino, G; Florio, C; Galgani, S; Pesci, I; Amato, MP; Rovaris, M; Gazzola, P; Lus, G; Maimone, D; Grimaldi, LM; Bergamaschi, R; Granella, F; Bertolotto, A; Totaro, R; Vianello, M; Bellantonio, P; Cavalla, P; Di Battista, G; Spitaleri, D; Tedeschi, G; Valzania, F; Scarpini, E; Gatto, M; Valentino, P; Mantegazza, R; Rezzonico, M; Passarella, B; Avolio, C; Logullo, FO; Cavalletti, G; Corea, F; Clerico, M; Lugaresi, A; Patti, F
F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation
2002-01-01 Cavalla, P.; Fiano, V.; Ghimenti, C.; Mutani, R.; Schiffer, D.
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial
2014-01-01 Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M.
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study
2017-01-01 Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study
2014-01-01 Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L.
Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis.
2011-01-01 Vercellino M; Trebini C; Romagnolo A; Chiavazza C; Masera S; Mattioda A; Capello E; Mancardi G; Giobbe D; Mutani R; Giordana MT; Cavalla P
NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS
2016-01-01 Allizond, V; Scutera, S; Piersigilli, G; Musso, T; Cavalla, P; Trebini, C; Marra, Es; Tullio, V; Mandras, N; Roana, J; Cuffini, Am; Banche, G
p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas
2002-01-01 Ghimenti, C.; Fiano, V.; Chiadò-piat, L.; Cavalla, P.; Schiffer, D.
p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas
2001-01-01 Schiffer, D.; Cavalla, P.; Fiano, V.; Vercellino, M.; Piva, R.; Pagano, M.
Prognostic factors in oligodendroglioma
1997-01-01 Schiffer D; Dutto A; Cavalla P; Chio' A; Giordana MT
Relationship between apoptosis and caspase 3 expression in malignant gliomas
2001-01-01 Schiffer D.; Fiano V.; Ghimenti C.; Cavalla P.
Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria.
2016-01-01 Allizond, V.; Scutera, S.; Piersigilli, G.; Musso, T.; Cavalla, P.; Trebini, C.; Marra, E.S.; Cristina, C.; Cuffini, A.M.; Banche, G
Role of PMNs in the control of microbial infections in multiple sclerosis patients.
2014-01-01 ALLIZOND, V; SCUTERA, S; ROSSI, S; MUSSO, T; CROCILLÀ, C; CAVALLA, P; CUFFINI, AM; MANDRAS, N; TULLIO, V; BANCHE, G
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta
2011-01-01 Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco.
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta
2009-01-01 Luca Durelli; Simona Rolla; Marinella Clerico; Laura Conti; Giulia Contessa; paolo Ripellino; Delon La Puma; Emanuela Viglietta; Antonio Uccelli; mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; daniela Boselli; Francesco Novelli
The increased risk of microbial infections in multiple sclerosis patients: interplay between disease-modifying therapies and human phagocytes
2019-01-01 Allizond Valeria ,Scutera Sara , Sparti Rosaria , Cavalla Paola , Musso Tiziana , Cuffini Anna Maria , Banche Giuliana
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A real-world study of Alemtuzumab in a cohort of Italian patients | 2019 | Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A | |
| Cyclins and CDKs in classic and anaplastic oligodendroglioma | 2003 | Cavalla, P; Fiano, V; Schiffer, D. | |
| Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas | 2002 | Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D. | |
| Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia | 2002 | Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P. | |
| Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience | 2019 | Chisari, C; Comi, G; Zaffaroni, M; Morra, VB; Trojano, M; Iaffaldano, P; Cocco, E; Centonze, D; Uccelli, A; Pozzilli, C; Salemi, G; De Luca, G; Cottone, S; Millefiorini, E; Salvetti, M; Aguglia, U; Costantino, G; Florio, C; Galgani, S; Pesci, I; Amato, MP; Rovaris, M; Gazzola, P; Lus, G; Maimone, D; Grimaldi, LM; Bergamaschi, R; Granella, F; Bertolotto, A; Totaro, R; Vianello, M; Bellantonio, P; Cavalla, P; Di Battista, G; Spitaleri, D; Tedeschi, G; Valzania, F; Scarpini, E; Gatto, M; Valentino, P; Mantegazza, R; Rezzonico, M; Passarella, B; Avolio, C; Logullo, FO; Cavalletti, G; Corea, F; Clerico, M; Lugaresi, A; Patti, F | |
| F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation | 2002 | Cavalla, P.; Fiano, V.; Ghimenti, C.; Mutani, R.; Schiffer, D. | |
| How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial | 2014 | Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M. | |
| How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study | 2017 | Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP | |
| Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study | 2014 | Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L. | |
| Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis. | 2011 | Vercellino M; Trebini C; Romagnolo A; Chiavazza C; Masera S; Mattioda A; Capello E; Mancardi G; Giobbe D; Mutani R; Giordana MT; Cavalla P | |
| NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS | 2016 | Allizond, V; Scutera, S; Piersigilli, G; Musso, T; Cavalla, P; Trebini, C; Marra, Es; Tullio, V; Mandras, N; Roana, J; Cuffini, Am; Banche, G | |
| p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas | 2002 | Ghimenti, C.; Fiano, V.; Chiadò-piat, L.; Cavalla, P.; Schiffer, D. | |
| p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas | 2001 | Schiffer, D.; Cavalla, P.; Fiano, V.; Vercellino, M.; Piva, R.; Pagano, M. | |
| Prognostic factors in oligodendroglioma | 1997 | Schiffer D; Dutto A; Cavalla P; Chio' A; Giordana MT | |
| Relationship between apoptosis and caspase 3 expression in malignant gliomas | 2001 | Schiffer D.; Fiano V.; Ghimenti C.; Cavalla P. | |
| Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria. | 2016 | Allizond, V.; Scutera, S.; Piersigilli, G.; Musso, T.; Cavalla, P.; Trebini, C.; Marra, E.S.; Cristina, C.; Cuffini, A.M.; Banche, G | |
| Role of PMNs in the control of microbial infections in multiple sclerosis patients. | 2014 | ALLIZOND, V; SCUTERA, S; ROSSI, S; MUSSO, T; CROCILLÀ, C; CAVALLA, P; CUFFINI, AM; MANDRAS, N; TULLIO, V; BANCHE, G | |
| T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta | 2011 | Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco. | |
| Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta | 2009 | Luca Durelli; Simona Rolla; Marinella Clerico; Laura Conti; Giulia Contessa; paolo Ripellino; Delon La Puma; Emanuela Viglietta; Antonio Uccelli; mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; daniela Boselli; Francesco Novelli | |
| The increased risk of microbial infections in multiple sclerosis patients: interplay between disease-modifying therapies and human phagocytes | 2019 | Allizond Valeria ,Scutera Sara , Sparti Rosaria , Cavalla Paola , Musso Tiziana , Cuffini Anna Maria , Banche Giuliana |